Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00250029 · ClinicalTrials.gov registry record · NA

Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen

A NA study, sponsored by New Mexico Cancer Research Alliance.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT00250029 is a NA study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00250029, a NA study, has completed, sponsored by New Mexico Cancer Research Alliance.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

1.1 To collect pathological tumor specimens of patients with metastatic colorectal cancer in a prospective fashion for correlative studies of response to an oxaliplatin based chemotherapy regimen. 1.2 To determine a gene expression profile that predicts response to an oxaliplatin based chemotherapy regimen in this cohort of patients.

Interventions

  • DRUG Oxaliplatin

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2004-04
Est. Completion 2006-03
Phase NA

What the Registry Record Tells You About NCT00250029

The ClinicalTrials.gov registry entry for NCT00250029 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Oxaliplatin is the first listed.

NCT00250029 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00250029 about?

NCT00250029 is a clinical study titled "Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen". 1.1 To collect pathological tumor specimens of patients with metastatic colorectal cancer in a prospective fashion for correlative studies of response to an oxaliplatin based chemotherapy regimen. 1.2 To determine a gene expression profile that predicts response to an oxaliplatin based chemotherapy...

What is the current status of trial NCT00250029?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2004-04. Estimated completion is 2006-03.

What interventions are being tested in trial NCT00250029?

The interventions under investigation include: Oxaliplatin (DRUG).

Who is sponsoring clinical trial NCT00250029?

This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.